NUTX trades 43.2% below Wall Street's consensus target of $310.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NUTX achieves its forward estimates and maintains a stable P/E multiple of 7.8x. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Nutex Health, Inc. (NUTX) has a Wall Street consensus price target of $310.00, based on estimates from 5 covering analysts. With the stock currently trading at $216.50, this represents a potential upside of +43.2%. The company has a market capitalization of $1.49B.
Analyst price targets range from a low of $310.00 to a high of $310.00, representing a 0% spread in expectations. The median target of $310.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, NUTX trades at a trailing P/E of 20.7x and forward P/E of 7.8x. Analysts expect EPS to grow +10.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $211.14, with bear and bull scenarios of $133.02 and $278.20 respectively. Model confidence stands at 42/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ADUSAddus HomeCare Corporation | $2.1B | $111.27 | $122.33 | +9.9% | Buy | 15.8x | 16 |
 AMSFAMERISAFE, Inc. | $441M | $23.59 | $32.00 | +35.7% | Buy | 11.9x | 6 |
 UHSUniversal Health Services, Inc. | $10.6B | $175.72 | $193.00 | +9.8% | Hold | 7.8x | 44 |
 THCTenet Healthcare Corporation | $22.3B | $258.62 | $283.36 | +9.6% | Buy | 12.2x | 32 |
 CYHCommunity Health Systems, Inc. | $384M | $2.72 | $2.94 | +8.1% | Hold | — | 37 |
 HCAHCA Healthcare, Inc. | $92.4B | $426.69 | $457.53 | +7.2% | Buy | 14.5x | 46 |
 SGRYSurgery Partners, Inc. | $1.7B | $13.32 | $18.00 | +35.1% | Buy | 32.7x | 22 |
 USPHU.S. Physical Therapy, Inc. | $1.3B | $83.72 | $90.00 | +7.5% | Buy | 30.4x | 13 |
 MCKMcKesson Corporation | $107.6B | $902.28 | $953.00 | +5.6% | Buy | 20.2x | 31 |
 CAHCardinal Health, Inc. | $53.5B | $228.30 | $273.22 | +19.7% | Buy | 18.2x | 33 |
Quick answers to the most common questions about buying NUTX stock.
The consensus Wall Street price target for NUTX is $310, representing 43.2% upside from the current price of $216.5. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NUTX has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $310 implies 43.2% upside from current levels.
With a forward P/E of 7.7895x, NUTX trades at a relatively low valuation. The consensus target of $310 implies 43.2% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $310 for NUTX, while the most conservative target is $310. The consensus of $310 represents the median expectation. Our quantitative valuation model projects a bull case target of $278 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NUTX is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NUTX stock forecast based on 5 Wall Street analysts shows a consensus price target of $310, with estimates ranging from $310 (bear case) to $310 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $211, with bear/bull scenarios of $133/$278.
Our quantitative valuation model calculates NUTX's fair value at $211 (base case), with a bear case of $133 and bull case of $278. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 42/100.
NUTX trades at a forward P/E ratio of 7.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on NUTX, with a "Buy" consensus rating and $310 price target (43.2% upside). 5 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NUTX analyst price targets range from $310 to $310, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $310 consensus represents the middle ground. Our model's $133-$278 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.